AR056787A1 - Sales y polimorfos farmaceuticos de un inhibidor del factor xa - Google Patents

Sales y polimorfos farmaceuticos de un inhibidor del factor xa

Info

Publication number
AR056787A1
AR056787A1 ARP060104900A ARP060104900A AR056787A1 AR 056787 A1 AR056787 A1 AR 056787A1 AR P060104900 A ARP060104900 A AR P060104900A AR P060104900 A ARP060104900 A AR P060104900A AR 056787 A1 AR056787 A1 AR 056787A1
Authority
AR
Argentina
Prior art keywords
salts
polymorphes
pharmaceutical
factor inhibitor
compound
Prior art date
Application number
ARP060104900A
Other languages
English (en)
Spanish (es)
Inventor
Craig Grant
James P Kanter
Graeme Langlands
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of AR056787A1 publication Critical patent/AR056787A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP060104900A 2005-11-08 2006-11-08 Sales y polimorfos farmaceuticos de un inhibidor del factor xa AR056787A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73522405P 2005-11-08 2005-11-08

Publications (1)

Publication Number Publication Date
AR056787A1 true AR056787A1 (es) 2007-10-24

Family

ID=38023988

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060104900A AR056787A1 (es) 2005-11-08 2006-11-08 Sales y polimorfos farmaceuticos de un inhibidor del factor xa
ARP160103799A AR106960A2 (es) 2005-11-08 2016-12-12 SALES Y POLIMORFOS FARMACÉUTICOS DE UN INHIBIDOR DEL FACTOR Xa

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP160103799A AR106960A2 (es) 2005-11-08 2016-12-12 SALES Y POLIMORFOS FARMACÉUTICOS DE UN INHIBIDOR DEL FACTOR Xa

Country Status (20)

Country Link
US (7) US7598276B2 (https=)
EP (2) EP1948608B1 (https=)
JP (2) JP5227178B2 (https=)
KR (1) KR101358574B1 (https=)
CN (2) CN101304971B (https=)
AR (2) AR056787A1 (https=)
AT (1) ATE549317T1 (https=)
AU (1) AU2006311544B2 (https=)
BR (1) BRPI0618362A2 (https=)
CA (1) CA2627086C (https=)
DK (1) DK1948608T3 (https=)
ES (1) ES2384116T3 (https=)
IL (2) IL190524A (https=)
NZ (2) NZ592533A (https=)
PE (2) PE20070717A1 (https=)
PT (1) PT1948608E (https=)
RU (1) RU2440986C2 (https=)
TW (1) TWI443088B (https=)
WO (1) WO2007056517A2 (https=)
ZA (1) ZA200803820B (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064642A2 (en) * 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
KR101195801B1 (ko) 2004-06-18 2012-11-05 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 억제제
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
PE20070717A1 (es) * 2005-11-08 2007-08-17 Millennium Pharm Inc Sal de maleato y polimorfo de [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro-(2-piridil))carboxamida
US20090186810A1 (en) * 2006-03-27 2009-07-23 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
NZ572418A (en) * 2006-05-05 2011-08-26 Millennium Pharm Inc Factor xa inhibitors
CN101595092B (zh) 2006-11-02 2012-02-01 米伦纽姆医药公司 合成因子xa抑制剂的医药盐的方法
KR101472765B1 (ko) * 2006-12-08 2014-12-15 밀레니엄 파머슈티컬스 인코퍼레이티드 경구용 Ｘａ 인자 억제제를 포함하는 단위 용량 제형 및 경구용 Ｘａ 인자 억제제를 사용하는 혈전증의 치료 방법
WO2008086226A2 (en) * 2007-01-05 2008-07-17 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
CL2008000070A1 (es) * 2007-01-17 2008-07-25 Lg Life Sciences Ltd Monosal del acido maleico (3-[({1-[(2-amino-9h-purin-9-il)metil]ciclopropil}oxi)metil]-8,8-dimetil-3,7-dioxo-2,4,6-trioxa-3 lambda 5-fosfanon-1-il-pivalato; composicion farmaceutica que comprende a dicha monosal; y uso para el tratamiento del virus h
EA020531B1 (ru) 2007-04-13 2014-11-28 Милленниум Фармасьютикалз, Инк. КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИКОАГУЛИРУЮЩЕГО СРЕДСТВА С СОЕДИНЕНИЕМ, КОТОРОЕ ДЕЙСТВУЕТ КАК ИНГИБИТОР ФАКТОРА Ха
KR101509829B1 (ko) 2007-05-02 2015-04-06 포톨라 파마슈티컬스, 인코포레이티드 혈소판 ａｄｐ 수용체 억제제로 작용하는 화합물을 이용한 병용요법
EP2915564B1 (en) 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
PE20091156A1 (es) * 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
MX2011004907A (es) 2008-11-14 2011-07-29 Portola Pharm Inc Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre.
EP3121271B1 (en) 2009-03-30 2019-07-24 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
ES2605801T3 (es) * 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
CN102762550B (zh) * 2009-12-17 2015-04-01 米伦纽姆医药公司 Xa因子抑制剂的盐和结晶形式
AR079491A1 (es) * 2009-12-17 2012-02-01 Millennium Pharm Inc Metodos de sintesis de inhibidores del factor xa tal como el betrixaban y composiciones farmaceuticas que contienen la base libre de betrixaban o su sal sustancialmente pura.
US8742120B2 (en) * 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
EA015918B1 (ru) * 2010-03-03 2011-12-30 Дмитрий Геннадьевич ТОВБИН УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa
AR082803A1 (es) 2010-09-01 2013-01-09 Portola Pharm Inc Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
AR082804A1 (es) * 2010-09-01 2013-01-09 Portola Pharm Inc Formas cristalinas de un inhibidor del factor xa
CN102952138B (zh) * 2011-08-17 2016-07-06 上海特化医药科技有限公司 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
US20150224091A1 (en) 2011-08-31 2015-08-13 Portola Pharmaceuticals, Inc. Prevention and treatment of thrombosis in medically ill patients
US20140346397A1 (en) 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
CN104341343B (zh) * 2013-07-24 2018-09-28 四川海思科制药有限公司 贝曲西班的晶型及其制备方法和用途
CN105085387A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 贝曲西班盐及其制备方法和用途
EP3750556A1 (en) 2014-08-20 2020-12-16 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote
WO2017091757A1 (en) 2015-11-24 2017-06-01 Portola Pharmaceuticals, Inc. Isotopically enriched betrixaban
CN106995405A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种贝曲西班马来酸盐无定型物及其制备方法
WO2017147522A1 (en) 2016-02-24 2017-08-31 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote
US20190300483A1 (en) * 2016-06-02 2019-10-03 Dr. Reddy's Laboratories Limited POLYMORPHS OF BETRlXABAN & ITS MALEATE SALT
EP3254674A1 (en) 2016-06-08 2017-12-13 Sandoz Ag Pharmaceutical compositions of betrixaban maleate
PT3472314T (pt) 2016-06-17 2021-06-18 Alexion Pharma Inc Preparação de derivados do fator xa
WO2018042320A1 (en) * 2016-08-30 2018-03-08 Dr. Reddy’S Laboratories Limited Salts of betrixaban and processes for preparation thereof
EP3293174A1 (en) * 2016-09-09 2018-03-14 Sandoz Ag Crystalline salts of betrixaban
WO2018069936A1 (en) 2016-10-13 2018-04-19 Mylan Laboratories Limited Polymorphs and solid dispersion of betrixaban and methods for the preparation thereof
CN108017576B (zh) * 2016-11-01 2022-06-21 石药集团中奇制药技术（石家庄）有限公司 一种贝曲西班及其盐酸盐的制备方法，以及它们的晶型
CN108586325A (zh) * 2017-03-16 2018-09-28 上海度德医药科技有限公司 一种Betrixaban中间体的制备方法
WO2018229796A2 (en) * 2017-06-14 2018-12-20 Mylan Laboratories Limited A process for betrixaban hydrochloride and betrixaban maleate salt
CN107868039A (zh) * 2017-11-27 2018-04-03 中国药科大学 一种贝曲沙班中间体n－（5－氯－2－吡啶基）－2－［（4－氰基苯甲酰基）氨基］－5－甲氧基苯甲酰胺的制备方法
WO2022211680A1 (ru) * 2021-03-30 2022-10-06 Общество С Ограниченной Ответственностью "Фармадиол" Способ получения антикоагулянта n-(5-хлорпиридин-2-ил)-2-({4-[этан-имидоил(метил)амино]бензоил}амино)-5-метилбензамид гидрохлорида
CN115057854A (zh) * 2022-04-19 2022-09-16 河北常山生化药业股份有限公司 马来酸阿伐曲泊帕中间体的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08504769A (ja) 1992-12-15 1996-05-21 コルバス・インターナショナル、インコーポレイテッド 因子Ｘａの新規インヒビター
GB9226238D0 (en) 1992-12-16 1993-02-10 Scherer Ltd R P Encapsulation apparatus and process
ES2193202T3 (es) 1994-12-02 2003-11-01 Yamanouchi Pharma Co Ltd Nuevo derivado de amidinonaftilo o sal de este.
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
AU730224B2 (en) 1996-12-23 2001-03-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
KR20010023364A (ko) 1997-08-27 2001-03-26 간자와 무츠와 3-아미디노아닐린 유도체, 활성화 혈액응고 제 ｘ 인자저해제 및 그것의 제조중간체
US6140351A (en) * 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
ES2316383T3 (es) * 1999-09-17 2009-04-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
WO2001064642A2 (en) * 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
PE20070717A1 (es) 2005-11-08 2007-08-17 Millennium Pharm Inc Sal de maleato y polimorfo de [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro-(2-piridil))carboxamida
CN101595092B (zh) 2006-11-02 2012-02-01 米伦纽姆医药公司 合成因子xa抑制剂的医药盐的方法

Also Published As

Publication number Publication date
TW200736221A (en) 2007-10-01
US20160101089A1 (en) 2016-04-14
NZ567992A (en) 2011-05-27
US7598276B2 (en) 2009-10-06
US9061019B2 (en) 2015-06-23
EP2431358A1 (en) 2012-03-21
CN102336702A (zh) 2012-02-01
AU2006311544B2 (en) 2012-03-08
US8557852B2 (en) 2013-10-15
PT1948608E (pt) 2012-05-24
US20070112039A1 (en) 2007-05-17
ZA200803820B (en) 2009-03-25
HK1115131A1 (en) 2008-11-21
PE20070717A1 (es) 2007-08-17
CN101304971A (zh) 2008-11-12
TWI443088B (zh) 2014-07-01
JP5227178B2 (ja) 2013-07-03
ES2384116T3 (es) 2012-06-29
US20140288028A1 (en) 2014-09-25
EP1948608A2 (en) 2008-07-30
RU2440986C2 (ru) 2012-01-27
JP2009514976A (ja) 2009-04-09
KR101358574B1 (ko) 2014-02-04
RU2008123055A (ru) 2009-12-20
US20190046510A1 (en) 2019-02-14
CN102336702B (zh) 2015-02-11
ATE549317T1 (de) 2012-03-15
CA2627086A1 (en) 2007-05-18
US20130064806A1 (en) 2013-03-14
US9555023B2 (en) 2017-01-31
DK1948608T3 (da) 2012-07-02
US20100063113A1 (en) 2010-03-11
IL190524A (en) 2013-02-28
AR106960A2 (es) 2018-03-07
WO2007056517A2 (en) 2007-05-18
IL190524A0 (en) 2008-12-29
US20170326119A1 (en) 2017-11-16
JP5662980B2 (ja) 2015-02-04
CN101304971B (zh) 2011-09-07
IL213487A0 (en) 2011-07-31
NZ592533A (en) 2012-08-31
KR20080065662A (ko) 2008-07-14
EP1948608B1 (en) 2012-03-14
BRPI0618362A2 (pt) 2011-08-30
PE20110070A1 (es) 2011-03-04
JP2012246323A (ja) 2012-12-13
AU2006311544A1 (en) 2007-05-18
CA2627086C (en) 2016-04-05
WO2007056517A3 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
AR056787A1 (es) Sales y polimorfos farmaceuticos de un inhibidor del factor xa
ES2519446T3 (es) Proceso para la preparación de ácido 4-amino-butírico sustituido con biarilo o derivados del mismo y su uso en la producción de inhibidores de NEP
ES2486267T3 (es) 2-(Fenil 2-fluoro-substituido)-6-amino-5-cloro-4-pirimidinacarboxilatos y su uso como herbicidas
ES2492497T3 (es) Perácidos alfa-ceto y métodos para su producción y uso
UA101036C2 (en) Substituted 1-(diazinyl) pyrazole-4-yl-acetic acids
CO6290677A2 (es) Procesos e intermediarios para la preparación de derivados de acido 5-bifenil-4-il-2-metilpentanoico.
CR7691A (es) Nuevo procedimiento de sintesis de ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
UY33226A (es) Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
AR065196A1 (es) Procedimiento para la preparacion de un derivado de bencimidazol
BRPI0506843A (pt) composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto
CL2024000609A1 (es) Proceso para sintetizar derivados de naftiridina y compuestos intermedios de los mismos.
EA200901563A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
AR063747A1 (es) Definilazetidinona sustituida con acido piperazina-1-sulfonico y que tiene propiedades farmacologicas mejoradas
MX2010003849A (es) Antagonistas de cgrp.
ES2527191T3 (es) Procedimiento e intermedios para la preparación de un ingrediente activo
AR075915A1 (es) Proceso para la obtencion de derivados de acido propionico
EA200900797A1 (ru) Способ синтеза производных 3-аминотетрагидрофуран-3-карбоновой кислоты и их применение в качестве лекарственных средств
UY33149A (es) Compuestos carboxamida y su uso como inhibidores iv de calpaina
EA200701470A1 (ru) Способы получения производных 4-(фенокси-5-метилпиримидин-4-илокси)пиперидин-1-карбоновой кислоты и родственных соединений
AR059375A1 (es) Procedimiento para produccion de 5-alcoxi-4-hidroximetilpirazol y compuestos
BR112013003992A2 (pt) método de produção
NI200500065A (es) Nuevos procesos para la sintesis industrial del diester metilico del 5-amino-3-carboximetil-4-ciano-2-acido tiofenecarboxilico y aplicacion a la sintesis de sales bivalentes de acido ranelico y de sus hidratos.
WO2007105021A3 (en) Duloxetine salts
AR066430A1 (es) Proceso para preparar inhibidores de aromatasa y forma cristalina de exemestano
CO6612175A2 (es) Metodo para producir 4,6-dialcoxi-2-cianometil-pirimidina e intermediarios sinteticos de esta

Legal Events

Date Code Title Description
FC Refusal